Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases.

Mycophenolate mofetil (MMF, CellCept R © ) has become the most frequently used immunosuppressive drug in kidney transplant recipients [1]. Since its approval for the prevention of acute rejection after kidney transplantation in 1995 in the USA and in 1996 in Europe, the use of azathioprine has been rapidly diminishing, giving way to the use of MMF. A second formulation of mycophenolic acid (MPA...

متن کامل

Diagnostic and Therapeutic Corner Therapeutic Drug Monitoring of Mycophenolic Acid

M ycophenolic acid (MPA)-based therapies are widely used in combination with calcineurin inhibitors as maintenance immunosuppression for kidney transplant recipients (1). The two MPA therapies used in clinical transplantation are mycophenolate mofetil (MMF [brand name CellCept, Roche Pharmaceuticals, Nutley, NJ]) and mycophenolate sodium (MPS [brand name Myfortic, Norvartis Pharmaceuticals, Nut...

متن کامل

Therapeutic Drug Monitoring of Valproic Acid in Patients with Monotherapy at Steady State

Objective(s) The role of therapeutic drug monitoring (TDM) in patient care has grown rapidly since its introduction three decades ago. The aim of present study was to evaluate the possible relationship between serum levels and the clinical response of valproic acid (VPA). Materials and Methods In the present study we evaluated a homogeneous group of adult patients receiving VPA monotherapy. ...

متن کامل

Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring.

BACKGROUND AND OBJECTIVES Mycophenolate mofetil (MMF) is an immunosuppressive drug used in renal transplant patients. Upon oral administration it is hydrolyzed to the active agent mycophenolic acid (MPA). In renal transplant recipients, MMF therapy is optimal when the area under the curve of MPA is 30 to 60 mg·h/L. When MMF doses are adjusted, a linear relationship between dose and MPA exposure...

متن کامل

Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation.

With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need for more accurate drug dosing has become evident. Personalized immunosuppressive therapy requires better strategies for avoidance of drug-related toxicity while maintaining efficacy. Few studies have assessed the clinical usefulness of therapeutic drug monitoring (TDM) of MPA in solid organ transplantati...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Nephrology Dialysis Transplantation

سال: 2008

ISSN: 0931-0509,1460-2385

DOI: 10.1093/ndt/gfn497